1,2,3‐Triazole Derivatives as an Emerging Scaffold for Antifungal Drug Development against Candida albicans: A Comprehensive Review

Abstract Candida infections are most prominent among fungal infections majorly target immunocompromised and hospitalized patients and cause significant morbidity and mortality. Candida albicans is the notorious and most prevalent among all pathogenic Candida strains. Its emerging resistance toward available antifungal agents making it hard to tackle and emerging as global healthcare emergency. Simultaneously, 1,2,3‐triazole nucleus is a privileged scaffold that is gaining importance in antifungal drug development due to being a prominent bioactive linker and isostere of triazole based antifungal class core 1,2,4‐triazole. Numerous reports have been updated in scientific literature in last few decades related to utilization of 1,2,3‐triazole nucleus in antifungal drug development against Candida albicans . Present review will shed light on various preclinical studies focused on development of 1,2,3‐triazole derivatives targeting Candida albicans along with brief highlight on clinical trials and newly approved drugs. Structure‐activity relationship has been precisely discussed for each architect along with future perspective that will help medicinal chemists in design and development of potent antifungal agents for tackling infections derived from Candida albicans .